Sarah Greenhalgh, MD and co-founder of BSF Enterprise (LON:BSFA) wholly owned subsidiary Kerato, on how the tissue engineering specialist is commercialising its cutting-edge corneal regeneration technology
Kerato, is well down the path to commercialising corneal regeneration technology, a potentially life-changing treatment for millions of sufferers.
Currently, an estimated 55% of the world’s population do not have access to donor material needed for transplants, currently one of the only treatments for coronal damage. With 185,000 procedures per annum corneas are the most frequently transplanted human tissue worldwide, but this approach is not universally suitably, especially in some developing world economies where access to suitable medical facilities is limited.
The company’s research is focused on the development of corneal regenerative therapies, specifically its LiQD Cornea, injected via a single use medical device to rebuild corneas as host cells interact with Kerato’s patented tissue technology.
Preclinical studies have already demonstrated the effectiveness of the treatment, and Kerato are now in the process of designing clinical trials that could see LiQD Cornea available to patients by 2028. A parallel development project to deliver a veterinary version of the product is expected to deliver first revenues even sooner, by 2025.
Speaking to us from the company’s laboratory, managing director and co-founder Sarah Greenhalgh explains how she’s putting her 20 years of expertise in commercialising R&D to ensure Kerato’s life-changing technology achieves its enormous potential.
In this interview, investors will hear:
The science behind Kerato’s LiQD Cornea, and how it has the potential to be a life-changing treatment for millions of those vision-impaired who cannot easily access corneal transplants.
The advantages the treatment offers over the traditional transplant approach and how these can lower the cost of treating corneal problems, including reducing the cost of delivery and eliminating the potential for transplant rejection.
Preclinical trial success, and how the next phase of trials is being designed in conjunction with practitioners to best demonstrate the treatments efficacy and safety.
The adjacent opportunity in the veterinary market that could see first revenues delivered as early as 2025.
Reasons to add BSFA to your watchlist:
Deep group expertise in tissue engineering, with applications across multiple industries including lab-grown leather and synthetic meat and interest from global partners
Proven laboratory progress, with commercial expertise to turn patent protected intellectual property into meaningful long-term revenue streams
Sarah Greenhalgh, MD and co-founder of BSF Enterprise subsidiary Kerato, was interviewed by John Hughman for focusIR.
